USA: Biotechnology Abzena Opts for Sartorius to Equip Integrated CDMO Facilities
Abzena has selected Sartorius Stedim to equip its integrated CDMO facilities in Bristol for the development and GMP manufacture of antibody drug conjugates and San Diego for the development and GMP manufacture of monoclonal antibodies and other recombinant proteins.
Göttingen/Germany — The German company will provide both facilities with end-to-end process solutions in single-use (SU) format. It will equip Abzena’s San Diego process development lab with technologies such as Ambr 250, enabling fast scale up to 500 liters initially and later to the 2,000 liters scale single-use bioreactor for its centre of excellence in clinical manufacturing.
In addition to having selected the company's single-use technologies for antibody and ADC production, the Abzena facilities will feature Umetrics process analytics software throughout the process ensuring that all the data captured throughout molecule development is transformed into process knowledge.